Michael E. Goldberg is David Mahoney Professor of Brain and Behavior in the departments of neuroscience, neurology, psychiatry and ophthalmology at Columbia University College of Physicians and Surgeons, director of the Mahoney-Keck Center for Brain and Behavior Research, and is an active clinical neurologist. His neuroscience research focuses on the physiological basis of cognitive processes such as visual attention, spatial perception and decision-making. He earned his M.D. from Harvard Medical School in 1968. From 1978 to 2001, Goldberg was a senior investigator at the Laboratory of Sensorimotor Research at the National Eye Institute in Bethesda, Maryland. He is a fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science, and an elected member of the National Academy of Sciences. He is a past president of the Society for Neuroscience, and now chair of the society’s Committee on Animals in Research.
Michael E. Goldberg
David Mahoney Professor of Brain and Behavior
Columbia University
Explore more from The Transmitter
Neuro’s ark: Understanding fast foraging with star-nosed moles
“MacArthur genius” Kenneth Catania outlined the physiology behind the moles’ stellar foraging skills two decades ago. Next, he wants to better characterize their food-seeking behavior.
Neuro’s ark: Understanding fast foraging with star-nosed moles
“MacArthur genius” Kenneth Catania outlined the physiology behind the moles’ stellar foraging skills two decades ago. Next, he wants to better characterize their food-seeking behavior.
Largest leucovorin-autism trial retracted
A reanalysis of the data revealed errors and failed to replicate the results.
Largest leucovorin-autism trial retracted
A reanalysis of the data revealed errors and failed to replicate the results.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.